Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Net Income: 2012-2024

Historic Net Income for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Dec 2024 value amounting to $148.4 million.

  • Amphastar Pharmaceuticals' Net Income fell 57.09% to $17.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.9 million, marking a year-over-year decrease of 35.76%. This contributed to the annual value of $148.4 million for FY2024, which is 8.91% up from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its Net Income stood at $148.4 million for FY2024, which was up 8.91% from $136.2 million recorded in FY2023.
  • Amphastar Pharmaceuticals' Net Income's 5-year high stood at $148.4 million during FY2024, with a 5-year trough of $1.1 million in FY2020.
  • Its 3-year average for Net Income is $124.1 million, with a median of $136.2 million in 2023.
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' Net Income crashed by 98.27% in 2020, and later soared by 5,689.33% in 2021.
  • Amphastar Pharmaceuticals' Net Income (Yearly) stood at $1.1 million in 2020, then skyrocketed by 5,689.33% to $63.5 million in 2021, then surged by 38.32% to $87.8 million in 2022, then surged by 55.08% to $136.2 million in 2023, then climbed by 8.91% to $148.4 million in 2024.